KOSDAQBiotech & Pharma322510

JLK

₩3,660▼ 2.14%2026-11-18 close
Market Cap
₩94.2B
Turnover
₩300M
Volume
80K
Shares out.
25.7M
PER
—
PBR
3.2×
EPS
-₩650
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales rebound, losses persist; overseas results in focus

JLK's sales rose for two straight quarters in the second and third quarters of 2026, but operating and net losses have continued for five consecutive quarters, so whether overseas sales in Japan and the US can change the earnings structure is the key point to watch.

  1. 1

    Sales in 2025 were KRW 3.34 billion, up 133.9% year on year, but the operating loss widened to KRW 13.2 billion.

  2. 2

    Third-quarter 2026 sales were KRW 551 million, rising for a second straight quarter but down 38.5% from a year earlier.

  3. 3

    The net loss attributable to controlling shareholders totaled KRW 16.7 billion over the last four quarters, and operating cash flow in 2025 was -KRW 12.3 billion.

  4. 4

    In Japan JLK has seven stroke-related device certifications and five regional distribution partners, while in the US it has built a stroke AI product line with FDA clearances.

  5. 5

    In November 2026 JLK joined the K-AI Full-stack Alliance led by Intel Korea as an early member, but technical validation and actual hospital adoption remain separate steps to be proven.

02

Business structure

JLK is a medical AI company centered on stroke diagnosis and treatment. Its CT perfusion analysis solution JLK-CTP quantifies the infarct core and the hypoperfused area to help clinicians plan treatment.

A 2025 news report said the company holds 12 stroke diagnosis solutions covering the acute stage through rehabilitation. Its business model is moving from selling products one at a time toward subscription plans that bundle several solutions.

Revenue is centered on subscription supply to tertiary general hospitals and regional hub hospitals in Korea, and the company named expanded supply and higher clinical use of its stroke AI portfolio as the main drivers of 2025 sales growth. Japan is the most active overseas market.

JLK has secured seven stroke-related device certifications there and built sales cooperation with five regional distributors, combining direct sales by its local subsidiary to large hospitals with distributor sales to regional hub facilities.

The US market has been built through FDA clearances, and a 2025 report counted five approved products, one for prostate cancer and four for stroke. On the technology side, JLK ran its medical multimodal LLM platform JOOMED on Intel GPU environments in July 2026 and compared the results with an NVIDIA-based system. In November 2026 it joined the K-AI Full-stack Alliance led by Intel Korea as an early member.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩900M-₩2.7B−298.9%
2025Q4₩900M-₩4.3B−478.7%
2026Q1₩400M-₩3.4B−814.4%
2026Q2₩500M-₩3.3B−643.5%
2026Q3₩600M-₩3.1B−566.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩3.4B-₩8.6B-₩9B−252.6%−54.2%118.9%
2023₩2.5B-₩7.1B-₩7.3B−287.2%−62.4%182.8%
2024₩1.4B-₩12.7B-₩13.5B−891.9%−27.3%51.3%
2025₩3.3B-₩13.2B-₩13.6B−395.3%−32.9%79.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On an annual basis from regular reports, sales were KRW 3.42 billion in 2022, KRW 2.49 billion in 2023, KRW 1.43 billion in 2024 and KRW 3.34 billion in 2025. Sales fell 27.1% in 2023 and 42.6% in 2024 before rising 133.9% in 2025, with 2022 the largest year and 2024 the smallest in the 2022 to 2025 period.

Operating losses were KRW 8.63 billion, KRW 7.15 billion, KRW 12.7 billion and KRW 13.2 billion, a run of four consecutive years of losses. The loss narrowed in 2023 and widened in 2024 and 2025.

Operating losses widened in 2025 even as sales rebounded, and the company attributed this to higher operating costs in the US and Japan. Operating margin was -252.6% in 2022, -891.9% in 2024 and -395.3% in 2025, so the deepest margin came in the year sales were smallest.

Net loss attributable to controlling shareholders was KRW 9.01 billion, KRW 7.32 billion, KRW 13.5 billion and KRW 13.6 billion from 2022 to 2025, while total net loss including non-controlling interests was KRW 13.6 billion in 2025.

Operating cash flow was -KRW 7.9 billion in 2022, -KRW 6.38 billion in 2023, -KRW 10.9 billion in 2024 and -KRW 12.3 billion in 2025. Debt-to-equity, calculated as total liabilities divided by total equity, was 118.9%, 182.8%, 51.3% and 79.9% over the same years.

At year-end 2025, total equity was KRW 41.4 billion, all attributable to controlling shareholders, and total liabilities were KRW 33.1 billion.

Quarterly sales went from KRW 895 million in 3Q 2025 and KRW 897 million in 4Q 2025 to KRW 412 million in 1Q 2026, a 54.1% decline, then rose to KRW 520 million in 2Q and KRW 551 million in 3Q 2026, two straight quarters of growth. Third-quarter 2026 sales were still down 38.5% from a year earlier.

Operating losses were KRW 2.68 billion in 3Q 2025, KRW 4.29 billion in 4Q 2025, KRW 3.35 billion in both 1Q and 2Q 2026, and KRW 3.12 billion in 3Q 2026. The 3Q 2026 operating loss was smaller than in the prior quarter but larger than a year earlier.

Net loss attributable to controlling shareholders was KRW 2.17 billion, KRW 5.4 billion, KRW 3.81 billion, KRW 3.74 billion and KRW 3.77 billion across the last five quarters, totaling KRW 16.7 billion over the last four.

Sales have recovered from the 1Q 2026 low, but operating losses have stayed in the KRW 3 billion range, which suggests the added revenue has not yet offset the fixed cost base.

05

Industry analysis

Analysts broadly see the medical AI sector moving from regulatory approvals toward real sales and profit structures.

Hanyang Securities said in a March 2026 report that JLK had entered the stage where its approvals and reference building connect to actual revenue and earnings, and it presented 2026 as an important turning point.

The same report said valuation criteria are shifting from whether approvals were obtained toward sales indicators such as the number of installed hospitals, subscription expansion and entry into insurance reimbursement.

Japan is known as a market that is accelerating AI adoption for high-cost conditions such as stroke because of heavy medical spending from an aging population.

Citing an international medical information portal, a 2025 report said Japan's medical AI market was USD 1.1 billion in 2022 and is projected to grow to USD 8.9 billion by 2030. The US is known as the fastest-growing market for stroke AI software.

Among domestic peers, a 2025 report described JLK as holding the largest number of FDA 510(k) clearances and submissions for stroke AI in Korea. Because hospitals run different servers and IT environments, technology that reduces dependence on specific hardware is seen as a variable for expansion.

Technical validation and actual hospital adoption are separate steps, so commercial track record and new customer wins are likely to serve as the benchmark for business results.

06

Outlook

In its February 2026 annual results disclosure, JLK cited expanding overseas operations, centered on Japan and the US, as an additional growth driver for 2026.

The company announced in early November 2026 that it will hold a stroke AI seminar at the 42nd Japan Society of NeuroEndovascular Therapy meeting (JSNET 2026) in Tokyo from November 19 to 21. The company plans to use the meeting to broaden cooperation with Japanese clinicians and discussions on hospital adoption.

Its sales network aims to combine existing regional distributors with new partners to cover the whole of Japan from Hokkaido to Okinawa.

On Japanese approvals, a 2025 report said at least two additional approvals were expected in 2026, and the same report raised the view that JLK-CTP was likely to obtain Japanese insurance reimbursement in the first half.

No announcement confirming the timing of reimbursement had been made at the time of writing, so whether overseas sales show up in reported results is the next point to check. In a 2025 report, the company set goals of entering 500 hospitals by 2026 and 2,200 hospitals by 2028.

The Intel alliance participation announced on November 13, 2026 aims to develop AI that runs across different server environments and to explore commercialization.

Because a gap remains between technical validation and commercial rollout, whether quarterly sales keep rising after 4Q 2026 will be the benchmark for the outlook.

07

Valuation

PER
—
PBR
3.2×
ROE
-43.1%
EPS
-₩650
BPS
₩1,200
Dividend per share
₩0

The PER cannot be calculated because the last four quarters show net losses attributable to controlling shareholders. For that reason the price-to-book ratio, an asset-based multiple, is the main axis for valuation comparison.

The current PBR measures market capitalization against total equity of KRW 41.4 billion at year-end 2025, and it sits in a range that carries a premium over net asset value.

A Sangsang Securities report from October 2024 cited low PBR and PER levels at the time, and the current multiple is clearly higher than in that period. No dividend has been paid, so there is effectively no dividend yield support.

Valuation views in 2024 were built on the assumption that overseas sales would materialize, so today's multiple can be read as reflecting expectations for that conversion. On the earnings side, whether the sales recovery leads to a narrower operating loss will determine the quality of the asset value the PBR describes.

In a March 2026 report, Sangsang Securities did not present a target price, and Hanyang Securities also presented no investment rating or target price while calling 2026 a turning point.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Overseas approval base in place

In Japan JLK has seven stroke-related device certifications and a sales cooperation system with five regional distributors. In the US it holds several FDA-cleared products, and a 2025 report described it as having the largest number of stroke AI FDA 510(k) clearances and submissions in Korea. The company's stated direction is to raise the share of overseas sales gradually.

Early signs of a sales rebound

Sales in 2025 were KRW 3.34 billion, up 133.9% year on year, and sales rose for two straight quarters in the second and third quarters of 2026. The company says subscription AI supply is expanding to tertiary general hospitals and regional hub hospitals. Because the sales base was small, the high growth rates also partly reflect that starting point.

Brokerage view of a structural shift

Hanyang Securities viewed 2026 as a turning point where a medical AI company moves from approvals to revenue linkage. In a March 2026 report, Sangsang Securities said it expected progress in exports in the second half, and neither firm presented a target price.

09

Bear factors

Losses persist and widen

Operating losses ran for four consecutive years from 2022 to 2025 and widened to KRW 13.2 billion in 2025. The company has posted losses for five consecutive quarters from 3Q 2025 to 3Q 2026, and the net loss attributable to controlling shareholders totaled KRW 16.7 billion over the last four quarters. The operating margin was -395.3% in 2025.

Limits to the quarterly sales recovery

First-quarter 2026 sales fell 54.1% from the prior quarter, and third-quarter 2026 sales were down 38.5% from a year earlier. The third-quarter 2026 operating loss of KRW 3.12 billion was smaller than in the prior quarter but larger than a year earlier.

A MEGA Economy report noted that technical validation and actual hospital adoption are different, and that commercial results will serve as the benchmark.

Cash flow and capital structure pressure

Operating cash flow went from -KRW 7.9 billion in 2022 to -KRW 12.3 billion in 2025, a larger outflow. Debt-to-equity rose from 51.3% in 2024 to 79.9% in 2025. Reports have covered a KRW 11.9 billion convertible bond issuance, so future funding arrangements remain an important variable.

10

Risk factors

Delayed conversion of overseas sales

Japan and US contributions are not yet clearly visible in the reported results. The company says it will gradually raise the share of overseas sales, but no specific share appears in the reported figures.

A 2025 report suggested Japanese reimbursement in the first half, yet no confirmed announcement on timing has been made.

Financial and funding risk

Total equity at year-end 2025 was KRW 41.4 billion and total liabilities were KRW 33.1 billion. Operating cash outflows have persisted, reaching -KRW 12.3 billion in 2025. If losses continue, funding needs may grow, and the effect of methods such as convertible bonds on shareholder value also matters.

Regulation, competition and technology compatibility

The business depends on regulatory approvals such as those from the FDA and Japan's PMDA, along with distribution partners, so delays in approvals or reimbursement directly affect sales timing.

Because hospital server environments differ, hardware-compatible technology is required, and the company competes with domestic and overseas stroke AI providers for hospital adoption.

11

What to watch next

  1. November 19–21, 2026

    Stroke AI seminar at JSNET 2026. The check point is whether Japanese clinicians' interest leads to distribution agreements or hospital adoption discussions.

  2. Early February 2027

    Expected timing of preliminary 2026 annual results. In 2025 the sales disclosure came on February 6, 2026, so on a similar schedule the annual sales and operating loss trend would first be visible here.

  3. End of March 2027

    Filing deadline for the 2026 annual business report. It will confirm the final profit and loss, the composition of overseas sales and the debt-to-equity ratio as reported figures.

  4. Mid-May 2027

    Filing deadline for the 2027 first-quarter report. Whether first-quarter 2027 sales hold at or above the KRW 551 million of 3Q 2026 is the check point for the quarterly growth trend.

12

Overall view

JLK's sales rose 133.9% in 2025, showing that its subscription AI supply is producing measurable results, but the KRW 13.2 billion operating loss and four consecutive years of losses have not yet changed.

Third-quarter 2026 sales rose for a second straight quarter but were down 38.5% from a year earlier, and the net loss attributable to controlling shareholders totaled KRW 16.7 billion over the last four quarters.

Strengths include seven Japanese certifications, five distribution partners, a set of US FDA-cleared products, and a brokerage view that evaluation is shifting toward sales indicators.

Weaknesses include overseas sales not yet showing a clear share in reported results, a larger operating cash outflow of -KRW 12.3 billion in 2025, and a higher debt-to-equity ratio of 79.9% in 2025.

On valuation, the PER cannot be calculated and the PBR sits in a range above net asset value, which suggests the market is pricing in expectations for overseas sales.

The next checkpoints are distribution and hospital adoption news after the November 2026 Japanese conference, preliminary annual results in early 2027 and the confirmed profit and loss in the 2026 annual report.

Whether the overseas sales share and operating margin improve will be the benchmark for the direction of earnings.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. newspim.com
  2. pinpointnews.co.kr
  3. megaeconomy.co.kr
  4. etoday.co.kr
  5. paxnet.co.kr
  6. supple.kr
  7. m.news.nate.com
  8. pharm.edaily.co.kr
  9. whosaeng.com
  10. getnews.co.kr
  11. files-scs.pstatic.net
  12. littlebproject.com
  13. dailyinvest.kr
  14. dailyinvest.kr
  15. littlebproject.com
  16. kr.investing.com
  17. marketin.edaily.co.kr
  18. littlebproject.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis